Ir para o conteúdo principal

Praxis Precision Medicines Inc (NASDAQ: PRAX) — Perfil da empresa, notícias e dados financeiros

Logo de Praxis Precision Medicines Inc
PRAX Praxis Precision Medicines Inc
Praxis Precision Medicines Inc primary media
Perfil da empresa

Praxis Precision Medicines Inc

Praxis Precision Medicines (NASDAQ:PRAX) specializes in developing groundbreaking treatments focused on altering the course of neurological disorders. With a passionate commitment to innovation in the realm of brain health, Praxis aims to unlock new possibilities for individuals grappling with epilepsy, depression, and other psychiatric and neurological conditions. At the core of their operations lies a dedication to precision medicine - an approach that tailors treatment to the individual's unique genetic makeup, potentially revolutionizing patient care and outcomes in the neuroscience field. Their projects span from early research to clinical trials, all with the objective of delivering therapies that can profoundly change lives. By concentrating their efforts on understanding the genetic underpinnings of neurological disorders, Praxis is paving the way for more effective and personalized treatments.

Resumo

Public USParticipação acionária
2015Ano de fundação
99Funcionários
Massachusetts, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Praxis Precision Medicines Inc

  • Development of treatments for central nervous system disorders including epilepsy and psychiatric diseases, focusing on genetic targets.
  • Innovations in gene editing technologies aimed at precise corrections for genetic disorders.
  • Advancement in personalized medicine, utilizing genomics for tailored treatments.
  • Research on breakthrough therapies for rare neurological diseases, dedicating to finding cures.
  • Projects dedicated to improving diagnostics for early and accurate detection of neurological conditions.
  • Collaborations with academic and medical institutions to accelerate drug development and bring therapies to market faster.

equipe executiva do Praxis Precision Medicines Inc

  • Marcio Silva De'SouzaPresident, CEO & Director
  • Timothy Edwin KellyCFO & Treasurer
  • Alex NemiroffGeneral Counsel & Secretary
  • Steven PetrouCo-Founder and President of Research & Development
  • Megan T. SniecinskiChief Operating Officer
  • Karl HansenChief Technical Operations Officer
  • Kelly McCueChief People Officer
  • Alyssa J. S. WyantChief Regulatory & Quality Officer
  • Brian SparChief of Staff
  • Orrin DevinskyHead of Clinical Strategy

Principais indicadores financeiros

Resultados divulgados pela Praxis Precision Medicines Inc, em USD.

Cap. de mercado
7,5 bi
Receita (TTM)
7,5 mi
P/L
—
LPA (diluído, TTM)
-12.9
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Praxis Precision Medicines Inc
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-326,2 mi-303,3 mi
8,6 mi-200,2 mi-182,8 mi
2,4 mi-126,4 mi-123,3 mi
1,5 mi-215 mi-213,1 mi